



HAL
open science

Impact of the Timing of Antibiotic Administration on Digestive Colonization with Carbapenemase-Producing Enterobacteriaceae in a Murine Model

Rémi Le Guern, Teddy Grandjean, Marvin Bauduin, Martin Figeac, Guillaume Millot, Aurore Loquet, Karine Faure, Eric Kipnis, Rodrigue Dessenin

► **To cite this version:**

Rémi Le Guern, Teddy Grandjean, Marvin Bauduin, Martin Figeac, Guillaume Millot, et al.. Impact of the Timing of Antibiotic Administration on Digestive Colonization with Carbapenemase-Producing Enterobacteriaceae in a Murine Model. *Antimicrobial Agents and Chemotherapy*, 2019, 63 (6), pp.e00360-19. 10.1128/AAC.00360-19 . hal-02566181

HAL Id: hal-02566181

<https://hal.science/hal-02566181>

Submitted on 12 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Impact of the Timing of Antibiotic Administration on Digestive Colonization with**
2 **Carbapenemase-Producing Enterobacteriaceae in a Murine Model**

3 **Author's names & affiliations :**

4 **Rémi Le Guern^{1,2}, Teddy Grandjean¹, Marvin Bauduin¹, Martin Figeac³, Guillaume**
5 **Millot¹, Aurore Loquet¹, Karine Faure^{1,4}, Eric Kipnis^{1,5}, Rodrigue Dessein^{1,2}**

6 1 : Univ. Lille, EA 7366 - Recherche translationnelle: relations hôte pathogènes, F-59000
7 Lille, France

8 2 : CHU Lille, Institut de Microbiologie, F-59000 Lille, France

9 3 : Univ de Lille, Plate-forme de Génomique Fonctionnelle et Structurale, F-59000 Lille,
10 France

11 4 : CHU Lille, Unité de Maladies Infectieuses, F-59000 Lille, France

12 5 : CHU Lille, Service de Réanimation Chirurgicale, F-59000 Lille, France

13 **Corresponding Author:**

14 Dr. Rodrigue Dessein, Univ. Lille, EA 7366 - Recherche translationnelle: relations hôte
15 pathogènes, F-59000 Lille, France; CHU Lille, Institut de Microbiologie, F-59000 Lille,
16 France; e-mail: rodrigue.dessein@chru-lille.fr

17

18 **Abstract: (75 words)**

19 While antibiotic use is a risk factor of carbapenemase-producing *Enterobacteriaceae*
20 (CPE) acquisition, the importance of timing of antibiotic administration relative to CPE
21 exposure remains unclear. In a murine model of gut colonization with NDM-1-producing
22 *Klebsiella pneumoniae*, a single injection of clindamycin within at most one week before
23 or after CPE exposure induced colonization persisting up to 100-days. Timing of
24 antibiotic administration relative to CPE exposure may be relevant to infection control
25 and antimicrobial stewardship approaches.

26 **Running title:** Timing of antibiotics relative to CPE exposure

27 (49 characters with spaces)

28 **Keywords:**

29 Carbapenemase, Gut Microbiota, NDM-1, *Klebsiella pneumoniae*, Murine model

30 **Abbreviations:**

31 CPE = carbapenemase-producing *Enterobacteriaceae*

32 Carbapenemase-producing *Enterobacteriaceae* (CPE) are an emerging public health
33 issue, considered a critical priority by the World Health Organization (1). Among CPE,
34 New Delhi metallo-beta-lactamase-1-(NDM-1)-producing *Enterobacteriaceae* are
35 particularly preoccupying. Indeed, NDM-1 confers resistance to most β -lactams,
36 including carbapenems, and has spread worldwide (2), raising fears of severe infections
37 without therapeutic options (3).

38 In the hospital setting, contact with a CPE-colonized patient or prior antibiotic use are
39 major risk factors for CPE acquisition (4, 5). Among antibiotics, anti-anaerobes (e.g.,
40 piperacillin-tazobactam or clindamycin) seem particularly at risk (6, 7).

41 While antibiotics are a known risk factor, the role of the timing of CPE exposure relative
42 to antibiotic administration is unclear. We describe a murine model of gut colonization
43 with NDM-1-producing *Klebsiella pneumoniae* following a single administration of
44 clindamycin and assess the effects of timing of clindamycin administration relative to
45 CPE exposure on effective CPE colonization.

46 The French Ethical Committee for Animal Experimentation approved this study (APAFIS
47 #7166). Seven-week-old C57BL/6 male mice housed under specific pathogen-free
48 conditions and a clinical isolate of *Klebsiella pneumoniae* producing NDM-1-
49 carbapenemase (8) were used.

50 First, we validated the murine model of CPE gut colonization. Mice were divided into
51 four groups with or without 24-hour CPE exposure in drinking water (10^7 CFU/mL at day
52 0) and/or intraperitoneal clindamycin (200 μ g) (Figure 1). CPE load was evaluated by
53 plating stool samples onto selective medium (lysogeny broth agar with 32 mg/L

54 cefotaxime and 6 mg/L vancomycin). In mice exposed to both CPE and clindamycin, 8.3
55 to 8.7 log CPE/g stools were recovered at Days 7 through 14 (Figure 1A). In mice
56 exposed to CPE without clindamycin, CPE load in stools briefly peaked at 5.6 log of
57 CPE/g of stool at Day 2 but fell below detection threshold from Day 7 onwards. Without
58 clindamycin administration, there was no effective colonization.

59 Microbiota alterations observed with CPE exposure and/or clindamycin injection were
60 analyzed by next-generation sequencing (n=2 per group) of ileal samples taken at Day 7
61 by 16S rDNA gene amplification using the Ion 16STM Metagenomics kit and sequencing
62 on the Ion PGM System (Life Technologies, Carlsbad, USA). Bioinformatic analyses
63 were performed using QIIME2 (9) and R phyloseq package (10). CPE exposure without
64 clindamycin did not alter gut microbiota compared to controls: more than 90% of 16S
65 rDNA sequences were classified as *Firmicutes*, either *Clostridiales* or *Lactobacilliales*
66 (Figure 1B, 1C). Clindamycin administration without CPE exposure led to an increase in
67 *Bacteroidetes* (approximately 45%) and *Proteobacteria*, mainly *Enterobacteriales* (up to
68 26%). Clindamycin administration with CPE exposure resulted in a major increase in
69 *Proteobacteria* (up to 84%), mostly *Enterobacteriales* (up to 76%).

70 To determine CPE colonization localization along the intestinal tract, intraluminal
71 contents from terminal ileum, caecum, colon, and stool samples were taken at Day 7 in
72 five CPE-exposed and clindamycin-treated mice. A higher load of CPE/g of digestive
73 contents was found in the caecum (8.2 log \pm 0.5), colon (8.0 log \pm 0.4) and feces (8.1 log
74 \pm 0.2) compared to ileum (5.0 log \pm 0.8, $p < 0.0001$) (Figure 1D).

75 Finally, to determine the effects of timing of clindamycin administration relative to CPE
76 exposure on effective CPE colonization, CPE exposed mice received clindamycin at
77 different days before or after CPE exposure (figure 2). Stool samples were collected
78 twice weekly for a month, then once weekly for two months to assess CPE load.
79 Clindamycin injection at most one week before or after CPE exposure was necessary to
80 achieve gut colonization (Figure 2). Indeed, when clindamycin was injected at either
81 Days-21/-14 or Days+14/+21, the mice were not durably colonized, despite CPE
82 exposure at Day-0.

83 The timing of antibiotics relative to CPE exposure is a key factor of effective CPE
84 colonization. In our murine model, a single clindamycin injection within a week before or
85 after CPE exposure induced gut colonization for at least 100 days. Remarkably, in a
86 study predating the “omics” era, van der Waaij *et al.* also demonstrated 2-week selective
87 window for persistent digestive colonization with streptomycin/neomycin resistant Gram-
88 negative bacteria following oral administration of these antibiotics (11). Other murine
89 models of digestive CPE colonization have been described. In one model, when mice
90 were exposed to KPC-producing *Klebsiella pneumoniae* three days after the first
91 administration of clindamycin, CPE load initially attained 10 log CFU/g of stool, then
92 decreased to 5-6 log CFU/g of stool five days after the last clindamycin injection (6). In
93 another model, in which mice were exposed to NDM-1-producing *Escherichia coli* four
94 days after the first administration of vancomycin, metronidazole, and ceftriaxone (12),
95 CPE load in stools was 2-3 log CFU/g (close to the detection limit) twenty days after
96 ending antimicrobials. In our model, with a single injection of clindamycin, CPE load over
97 7 log CFU/g of stool persisted for 100 days. Furthermore, our study is original in

98 assessing not only the window of opportunity for colonization after administration of
99 antibiotics, but also before and showing that this opportunity exists both one week
100 before and after antibiotics.

101 Gut microbiota analysis confirms that CPE exposure alone does not lead to colonization
102 since *Enterobacteriales*, which CPE belong to, remained undetected seven days after
103 exposure, similar to unexposed controls. Seven days after clindamycin administration,
104 there was a marked decrease in *Clostridiales* from over 75% to 30% at most, an
105 increase in *Bacteroidetes* (45%), and an appearance of *Enterobacteriales* (23%), even
106 without CPE exposure. *Enterobacteriales* are resistant to clindamycin; therefore their
107 expansion can be enhanced by clindamycin, as described previously in a murine model
108 of *Clostridium difficile* infection (13). Interestingly, in their pre-“omics” demonstration of a
109 selective window for digestive colonization induced by antibiotics, van der Waaij *et al.*,
110 using germ-free mice recolonized with the flora from mice in which colonization was no
111 longer possible late after antibiotic exposure, found (in preliminary experiments) that this
112 flora conferring what was termed “colonization resistance” was characterized by a major
113 proportion of *Clostridiales* (11). A more recent study using conventional culture methods
114 showed that antibiotics allowed colonization by the ESBL *E. coli* strain ST 131
115 regardless of effect on *Bacteroidales* (clindamycin) or not (cefuroxime, dicloxacillin) (14).
116 These results suggest that the timing of antimicrobials relative to CPE exposure in
117 providing ecologic space for implantation and expansion is an important parameter to
118 consider.

119 Clinical studies focusing on healthy travelers at high risk of being exposed to CPE or
120 other multidrug-resistant *Enterobacteriaceae* found a high rate of acquisition of

121 multidrug-resistant *Enterobacteriaceae* (15). Although initially at 51%, colonization was
122 short-lived as only 5% remained colonized three months after their return. In this
123 population of healthy travelers, only 10% reported antibiotic use during their trip. While
124 studies of acquisition and persistence of colonization by NDM-1-producing
125 *Enterobacteriaceae* after travel to endemic countries concern few subjects, larger
126 studies concentrating on extended spectrum β -lactamase-producing *Enterobacteriaceae*
127 show that a significant risk factor is the use of antimicrobials during travel (16). These
128 studies suggest that a healthy gut microbiota protects travelers exposed to CPE or other
129 multidrug-resistant *Enterobacteriaceae* from long-term colonization (17).

130 Antibiotic use is a major risk factor of CPE colonization (5). In a context of up to 50% of
131 antibiotic misuse (18, 19), avoiding an epidemic spread of CPE requires antimicrobial
132 stewardship approaches. Our study suggests that more than the general notion of prior
133 antibiotic use, it is the timing of antibiotics relative to CPE exposure that may be the
134 main factor explaining colonization with CPE. This could be a crucial parameter to take
135 into account in infection control and antimicrobial stewardship strategies. Indeed, our
136 study shows there may be a specific window of opportunity for CPE colonization relative
137 to antibiotics administration.

138 **Conflict of Interest**

139 No conflict of interest


140 **Funding Statement**

141 University of Lille

142 **Acknowledgments**

143 We would like to thank Cécile Villenet and Shéhérazade Sebda for their help to process
144 16S rDNA metagenomic sequencing samples.


145



146
 147 **Figure 1. Gut microbiota alteration using clindamycin is a prerequisite for durable**
 148 **colonization with carbapenemase-producing enterobacteria (CPE) alongside the**
 149 **intestinal tract. (A) Quantification of CPE load in stools depending on clindamycin**

150 administration and CPE exposure, 5 mice per group. Control group: no CPE exposure
151 and no clindamycin; CPE exposure group: CPE in drinking water for the first 24 hours
152 (Day 0) and no clindamycin; clindamycin group: no CPE exposure and intraperitoneal
153 injection of clindamycin at Day 0; CPE + clindamycin group: CPE in drinking water for
154 the first 24 hours (Day 0) and intraperitoneal injection of clindamycin at Day 0. (B-C)
155 Relative abundance of bacterial phyla in terminal ileum samples using next generation
156 16S rDNA sequencing. Same groups than in experiment 1A, 2 mice per group. (D)
157 Quantification of CPE load along the gastro-intestinal tract. Five mice were exposed to
158 CPE in drinking water for the first 24 hours (Day 0) associated with intraperitoneal
159 injection of clindamycin at Day 0. Luminal samples were taken at Day 14.

160



162

163 **Figure 2. Effective CPE colonization depends on the timing of clindamycin**
 164 **administration in relation to CPE exposure.** Twenty-one mice were all exposed to
 165 CPE for 24-hours in drinking water (Day 0). Clindamycin was injected once at one of the
 166 following timepoints before or after CPE exposure: Day-21, Day-14, Day-7, Day-0,
 167 Day+7, Day+14 or Day+21.

168 **References:**

169 1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C,
170 Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outtersson K, Patel J, Cavalieri M, Cox
171 EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, Group
172 WHOPPLW. 2018. Discovery, research, and development of new antibiotics: the WHO
173 priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 18:318-327.

174 2. Dortet L, Poirel L, Nordmann P. 2014. Worldwide dissemination of the NDM-type
175 carbapenemases in Gram-negative bacteria. *Biomed Res Int* 2014:249856.

176 3. Zowawi HM, Forde BM, Alfaresi M, Alzarouni A, Farahat Y, Chong TM, Yin WF, Chan KG,
177 Li J, Schembri MA, Beatson SA, Paterson DL. 2015. Stepwise evolution of pandrug-
178 resistance in *Klebsiella pneumoniae*. *Sci Rep* 5:15082.

179 4. Schwartz-Neiderman A, Braun T, Fallach N, Schwartz D, Carmeli Y, Schechner V. 2016.
180 Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae
181 (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients. *Infect*
182 *Control Hosp Epidemiol* 37:1219-25.

183 5. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. 2008.
184 Predictors of carbapenem-resistant *Klebsiella pneumoniae* acquisition among
185 hospitalized adults and effect of acquisition on mortality. *Antimicrob Agents Chemother*
186 52:1028-33.

187 6. Perez F, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ. 2011. Effect of antibiotic
188 treatment on establishment and elimination of intestinal colonization by KPC-producing
189 *Klebsiella pneumoniae* in mice. *Antimicrob Agents Chemother* 55:2585-9.

190 7. Hilliquin D, Le Guern R, Thepot Seegers V, Neulier C, Lomont A, Marie V, Legeay C,
191 Merrer J, Lepelletier D, Rogues AM, Grandbastien B, Lucet JC, Zahar JR. 2018. Risk factors
192 for acquisition of OXA-48-producing *Klebsiella pneumoniae* among contact patients: a
193 multicentre study. *J Hosp Infect* 98:253-259.

194 8. Le Guern R, Grandjean T, Faure K, Bauduin M, Kipnis E, Dessein R. 2018. Draft genome
195 sequences of two carbapenemase-producing *Klebsiella pneumoniae* strains isolated
196 from blood cultures. *Microbiol Resour Announc* 7:e01057-18.

197 9. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N,
198 Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE,
199 Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ,
200 Walters WA, Widmann J, Yatsunencko T, Zaneveld J, Knight R. 2010. QIIME allows analysis
201 of high-throughput community sequencing data. *Nat Methods* 7:335-6.

202 10. McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive
203 analysis and graphics of microbiome census data. *PLoS One* 8:e61217.

204 11. van der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-v. 1971. Colonization resistance of
205 the digestive tract in conventional and antibiotic-treated mice. *J Hyg (Lond)* 69:405-11.

206 12. Mahieu R, Cassisa V, Hilliquin D, Coron N, Pailhories H, Kempf M, Joly-Guillou ML,
207 Eveillard M. 2017. Impact of faecal microbiota transplantation on mouse digestive
208 colonization with two extensively resistant bacteria. *J Infect* 75:75-77.

209

- 210 13. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda C, Xavier J,
211 Pamer EG. 2012. Profound alterations of intestinal microbiota following a single dose of
212 clindamycin results in sustained susceptibility to *Clostridium difficile*-induced colitis.
213 *Infect Immun* 80:62-73.
- 214 14. Hertz FB, Lobner-Olesen A, Frimodt-Moller N. 2014. Antibiotic selection of *Escherichia*
215 *coli* sequence type 131 in a mouse intestinal colonization model. *Antimicrob Agents*
216 *Chemother* 58:6139-44.
- 217 15. Ruppe E, Armand-Lefevre L, Estellat C, Consigny PH, El Mniai A, Boussadia Y, Goujon C,
218 Ralaimazava P, Campa P, Girard PM, Wyplosz B, Vittecoq D, Bouchaud O, Le Loup G,
219 Pialoux G, Perrier M, Wieder I, Moussa N, Esposito-Farese M, Hoffmann I, Coignard B,
220 Lucet JC, Andremont A, Matheron S. 2015. High Rate of Acquisition but Short Duration of
221 Carriage of Multidrug-Resistant Enterobacteriaceae After Travel to the Tropics. *Clin*
222 *Infect Dis* 61:593-600.
- 223 16. Kantele A, Mero S, Kirveskari J, Laaveri T. 2016. Increased Risk for ESBL-Producing
224 Bacteria from Co-administration of Loperamide and Antimicrobial Drugs for Travelers'
225 Diarrhea. *Emerg Infect Dis* 22:117-20.
- 226 17. Ruppe E, Andremont A, Armand-Lefevre L. 2018. Digestive tract colonization by
227 multidrug-resistant Enterobacteriaceae in travellers: An update. *Travel Med Infect Dis*
228 21:28-35.
- 229 18. Dellit TH, Owens RC, McGowan JE, Jr., Gerding DN, Weinstein RA, Burke JP, Huskins WC,
230 Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious
231 Diseases Society of A, Society for Healthcare Epidemiology of A. 2007. Infectious
232 Diseases Society of America and the Society for Healthcare Epidemiology of America
233 guidelines for developing an institutional program to enhance antimicrobial stewardship.
234 *Clin Infect Dis* 44:159-77.
- 235 19. Chua KP, Fischer MA, Linder JA. 2019. Appropriateness of outpatient antibiotic
236 prescribing among privately insured US patients: ICD-10-CM based cross sectional study.
237 *BMJ* 364:k5092.

238